Susan M. Geyer

13.3k total citations
175 papers, 7.1k citations indexed

About

Susan M. Geyer is a scholar working on Genetics, Oncology and Hematology. According to data from OpenAlex, Susan M. Geyer has authored 175 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Genetics, 70 papers in Oncology and 57 papers in Hematology. Recurrent topics in Susan M. Geyer's work include Chronic Lymphocytic Leukemia Research (56 papers), Lymphoma Diagnosis and Treatment (48 papers) and Multiple Myeloma Research and Treatments (35 papers). Susan M. Geyer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (56 papers), Lymphoma Diagnosis and Treatment (48 papers) and Multiple Myeloma Research and Treatments (35 papers). Susan M. Geyer collaborates with scholars based in United States, Canada and Italy. Susan M. Geyer's co-authors include Thomas E. Witzig, Angela Dispenzieri, Morie A. Gertz, Rafaël Fonseca, Martha Q. Lacy, Neil E. Kay, S. Vincent Rajkumar, Robert A. Kyle, Tait D. Shanafelt and John A. Lust and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Susan M. Geyer

168 papers receiving 6.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Susan M. Geyer United States	41	2.9k	2.7k	2.7k	2.4k	2.0k	175	7.1k
Steven Le Gouill France	47	2.1k 0.7×	1.7k 0.6×	3.3k 1.2×	1.7k 0.7×	3.7k 1.8×	312	7.2k
Gérald Marit France	43	3.3k 1.1×	5.9k 2.2×	3.3k 1.2×	2.2k 0.9×	1.8k 0.9×	193	8.6k
Miloslav Beran United States	46	2.2k 0.7×	5.2k 1.9×	1.8k 0.7×	3.4k 1.4×	1.7k 0.8×	106	8.5k
Bruce D. Cheson United States	37	1.9k 0.6×	2.9k 1.1×	3.7k 1.4×	3.0k 1.2×	5.3k 2.6×	130	9.6k
Sonali M. Smith United States	40	1.3k 0.4×	1.3k 0.5×	3.3k 1.3×	2.3k 1.0×	4.2k 2.1×	263	6.8k
Jean‐François Rossi France	36	2.7k 0.9×	3.2k 1.2×	2.9k 1.1×	693 0.3×	926 0.5×	110	6.4k
Ingemar Turesson Sweden	46	4.0k 1.3×	6.2k 2.3×	3.5k 1.3×	1.8k 0.7×	860 0.4×	148	8.3k
Donna Reece Canada	48	4.9k 1.7×	5.2k 1.9×	3.8k 1.4×	1.1k 0.5×	906 0.4×	349	8.2k
Morton Coleman United States	47	1.6k 0.6×	2.1k 0.8×	3.0k 1.1×	3.3k 1.3×	4.8k 2.4×	306	8.2k
Vincent Ribrag France	46	2.0k 0.7×	962 0.4×	4.6k 1.7×	1.7k 0.7×	3.6k 1.8×	309	7.9k

Countries citing papers authored by Susan M. Geyer

Since Specialization

Citations

This map shows the geographic impact of Susan M. Geyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan M. Geyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan M. Geyer more than expected).

Fields of papers citing papers by Susan M. Geyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan M. Geyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan M. Geyer. The network helps show where Susan M. Geyer may publish in the future.

Co-authorship network of co-authors of Susan M. Geyer

This figure shows the co-authorship network connecting the top 25 collaborators of Susan M. Geyer. A scholar is included among the top collaborators of Susan M. Geyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan M. Geyer. Susan M. Geyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Batchelor, Tracy T., Amy S. Ruppert, Susan M. Geyer, et al.. (2024). Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101. Blood Advances. 8(12). 3189–3199. 6 indexed citations

Beaven, Anne, Susan M. Geyer, Jonathon B. Cohen, et al.. (2024). Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma. Blood. 144(Supplement 1). 1661.3–1661.3.

Chan, Jennifer A., Susan M. Geyer, Tyler Zemla, et al.. (2024). 1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses. Annals of Oncology. 35. S749–S749.

Chan, Jennifer A., Susan M. Geyer, Michael V. Knopp, et al.. (2023). LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET). Annals of Oncology. 34. S1292–S1292. 18 indexed citations

Abdallah, Nadine, Alexandra N. Smith, Susan M. Geyer, et al.. (2023). Conditional survival in multiple myeloma and impact of prognostic factors over time. Blood Cancer Journal. 13(1). 78–78. 12 indexed citations

Epstein‐Peterson, Zachary D., Andriy Derkach, Susan M. Geyer, et al.. (2022). Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Advances. 6(11). 3433–3439. 7 indexed citations

Galanis, Evanthia, S. Keith Anderson, Erin Twohy, et al.. (2022). Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neuro-Oncology Advances. 4(1). vdac041–vdac041. 6 indexed citations

Monk, Paul, Glenn Liu, Walter M. Stadler, et al.. (2015). Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 33(7_suppl). 146–146. 7 indexed citations

Hofmeister, Craig C., Nita Williams, Susan M. Geyer, et al.. (2014). A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. Leukemia & lymphoma. 56(4). 1043–1049. 8 indexed citations

10.

Havelange, Violaine, Parvathi Ranganathan, Susan M. Geyer, et al.. (2014). Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood. 123(15). 2412–2415. 39 indexed citations

11.

Uy, Geoffrey L., Ben L. Sanford, Guido Marcucci, et al.. (2013). Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001). Blood. 122(21). 2653–2653. 2 indexed citations

12.

Mesa, Ruben A., John Camoriano, Susan M. Geyer, et al.. (2007). A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia. 21(9). 1964–1970. 26 indexed citations

13.

Micallef, Ivana N., Brad S. Kahl, Matthew J. Maurer, et al.. (2006). A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B‐cell lymphoma. Cancer. 107(12). 2826–2832. 32 indexed citations

14.

Dispenzieri, Angela, Martha Q. Lacy, Steven R. Zeldenrust, et al.. (2006). The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 109(2). 465–470. 200 indexed citations

15.

Goel, Apollina, Angela Dispenzieri, Susan M. Geyer, et al.. (2006). Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Blood. 107(10). 4063–4070. 30 indexed citations

16.

Hayman, Suzanne R., Morie A. Gertz, Martha Q. Lacy, et al.. (2006). Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma.. Blood. 108(11). 3568–3568. 1 indexed citations

17.

Gertz, Morie A., Susan M. Geyer, Ashraf Badros, Brad S. Kahl, & Charles Erlichman. (2005). Early Results of a Phase I Trial of Oblimersen Sodium for Relapsed or Refractory Waldenström's Macroglobulinemia. Clinical Lymphoma. 5(4). 282–284. 21 indexed citations

18.

Dispenzieri, Angela, Martha Q. Lacy, S. Vincent Rajkumar, et al.. (2003). Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid. 10(4). 257–261. 97 indexed citations

19.

Abraham, Roshini S., Susan M. Geyer, Tammy Price-Troska, et al.. (2003). Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain–associated amyloidosis (AL). Blood. 101(10). 3801–3807. 186 indexed citations

20.

Kraft, W, et al.. (1980). Thrombocytopenia in feline infectious panleukopenia.. Kleintierpraxis. 25(3). 129–134. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact